Annual Report

The report presents Beximco Pharma's 2022-23 consolidated net sales of BDT 39,266.7 million, an increase of 13.3% year on year. It also describes an EHS Committee, environmental initiatives including water reuse and rooftop solar generation, and extensive occupational health and safety measures. The people section reports a parent-company workforce of 5,706 employees and 8,754 specialized training man-hours involving 605 team members. The report also records 14 new domestic generics and 33 new registrations of 19 generics across 17 overseas markets.